Home/ Stocks/ SRZN

Surrozen, Inc. Common

SRZN XNAS

$28.96 -1.79 (-5.82%) ▼ 15-min delayed

Open

$30.95

High

$30.95

Low

$28.55

Volume

69.2K

Market Cap

$336.24M

About Surrozen, Inc. Common

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 44 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$5.00M	$-127,505,000	$-11.65
FY 2025	$3.48M	$-242,026,000	$-32.37
Q3 2025	$983.0K	$-71,643,000	$-8.36
Q2 2025	$983.0K	$39.75M	$2.55

Related Market News

No specific coverage for SRZN yet. Check out our latest market news or earnings calendar.

Get SRZN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Surrozen, Inc. Common.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.